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Role of vascular endothelial growth factor in diabetic nephrop- tractive candidate in this regard because VEGF mark-
athy. edly increases vascular permeability and potently stimu-
Background. Vascular endothelial growth factor (VEGF) is lates the vascular endothelial cell to divide [2, 3]. Itsa potent cytokine that is considered to be an important media-
pathogenic role in diabetic retinopathy is widely accepted,tor in the pathogenesis of endothelial dysfunction in diabetes.
and it predominantly mediates the neoangiogenesis asso-Methods. This study investigates the effect of high glucose
on the signaling and production of VEGF in rat mesangial ciated with proliferative retinopathy [4, 5]. Endothelial
cells in culture and measures the urinary VEGF level in patients dysfunction, which is also associated with diabetic ne-
with different stages of diabetic nephropathy. To elucidate the phropathy, may play a pathogenic role in the develop-role of VEGF in vivo further, expression of VEGF in control
ment of diabetic renal disease [6, 7], but this remainsand diabetic kidneys was examined using immunohistochem-
speculative at this time.istry.
Results. A high ambient glucose concentration in the culture In this study, we examined the effects of a high-glucose
medium increased VEGF mRNA expression and protein pro- concentration in culture media on VEGF mRNA expres-
duction within 3 h in a concentration-dependent manner. A
sion and protein production in rat mesangial cells. Weprotein kinase C (PKC) inhibitor and PKC down-regulation
also established whether VEGF production depends oninhibited glucose-induced increases in VEGF production. Uri-
nary excretion of VEGF significantly increased according to the protein kinase C (PKC) pathway. In a human study,
the degree of proteinuria in patients with diabetes. A weak we determined the plasma and urine concentrations of
but significant correlation was found between urinary VEGF VEGF and searched for any relationship between these
excretion and the levels of serum creatinine, creatinine clear-
values and the severity of diabetic nephropathy. To un-ance, microalbuminuria, and proteinuria. Immunohistochemis-
derstand the role of VEGF in diabetic kidney diseasetry revealed marked differences in the extent of mesangial
VEGF staining between diabetic and control kidneys. Pro- further, renal biopsies from 20 patients with noninsulin-
nounced up-regulation of VEGF was observed in the glomeru- dependent diabetes mellitus (NIDDM) and 3 patients
lar epithelial cell in the early phase of diabetic kidney disease, with renal cell carcinoma undergoing nephrectomy werewhereas widespread expression of VEGF was found in the
stained with a rabbit anti-VEGF antibody.tubular segments, especially the proximal segment, in advanced
diabetic nephropathy.
Conclusions. These results suggest that VEGF may play a
METHODSrole in the pathogenesis of diabetic nephropathy.
Rat mesangial cell culture
Glomeruli were isolated from male Sprague-Dawley
Abnormalities in endothelial function, such as in- rats weighing an average of 100 g. The kidney was re-
creased endothelial permeability to macromolecules and moved and the glomeruli, isolated by differential sieving,
endothelial proliferation, may be involved in the patho- were incubated in collagenase and trypsin-EDTA (Gibco
genesis of diabetic microvascular complications [1]. Con- Laboratories, Bethesda, MD, USA), as described pre-
siderable research has focused on the pathogenesis of viously [8]. Mesangial cells (MCs) were identified by
endothelial dysfunction, but the exact mechanisms re- their characteristic stellate shape in cell culture and con-
main incompletely defined. firmed by immunofluorescent microscopy for the pres-
Vascular endothelial growth factor (VEGF) is an at- ence of actin and myosin and the absence of factor VIII
and cytokeratin (Synbiotics, San Diego, CA, USA). MCs
Key words: cytokines, diabetes mellitus, proteinuria. were maintained in normal glucose (5.5 mmol/L) Dul-
becco’s Modified Eagle Medium (DMEM) supplementedÓ 2000 by the International Society of Nephrology
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with 2 mmol/L l-glutamine, 10 mmol/L N-2-hydroxy- three splicing variants (VEGF120, VEGF164, and VEGF188).
The expected lengths of their PCR products are 330 baseethylpiperazine-N-2-ethanesulfonic acid (HEPES), 100
U/mL penicillin, 100 U/mL streptomycin, and 17% heat- pairs (bp) for VEGF120, 462 bp for VEGF164, and 514 bp
for VEGF188. The nucleotide sequences of each primerinactivated fetal bovine serum (FBS). For this study,
cells in the fourth to sixth passages were incubated at are as follows: sense 59-GACCCTGGTGGACATCTTC
CAGGA-39 and antisense 59-GGTGAGAGGTCTAG378C in humidified 5% CO2 in air.
TTCCCGA-39. The second set (rVEGF2 primer), which
Experimental design includes introns between amplification sites from exon 3
to exon 7, amplifies two splicing variants (VEGF164 andMCs were grown to subconfluence in 6-well plates in
the growth media, and then cultured for 48 hours in serum- VEGF188). The expected lengths of their PCR products
are 444 bp for VEGF164 and 372 bp for VEGF188. The nu-deprived medium containing 5 mmol/L d-glucose and
1% FBS, before being exposed to an experimental condi- cleotide sequences of each primer are as follows: sense
59-GACCCTGGTGGACATCTTCCAGGA-39 and anti-tion. Cells were divided into three experimental groups
according to the glucose concentration: The normal glu- sense 59-GTTTAACTCAAGCTGCCTCGC-39. b2m was
also amplified as an internal control, and the expectedcose group (NG), served as control; the medium glucose
group (MG) was incubated in 15 mmol/L d-glucose; and length of the PCR product was 188 bp. The nucleotide
sequences of the primers are as follows: sense 59-CAGAthe high glucose group (HG) was incubated in 30 mmol/L
d-glucose. As an osmotic control, MCs were cultured in TCTGTCCTTCAGCAAG-39 and antisense 59-GGAGT
AAACTGGTCCAGATG-39.media containing 5 mmol/L d-glucose and 25 mmol/L
d-mannitol. MCs grown in triplicate were harvested at Different numbers of PCR cycles were performed and
plotted against the densitometry measurements of the0, 3, 6, and 24 hours for extraction of total RNA and
protein. To evaluate whether VEGF production depends resulting PCR products to define the range in which
cycle number was linearly related to the amount of PCR-on the protein kinase C pathway, MCs were treated with
200 nmol/L calphostin C (Calbiochem, San Diego, CA, amplified product. Next, 5 mL PCR reaction product
were separated by electrophoresis through a 2% agaroseUSA) for 60 minutes before changing to the 30 mmol/L
d-glucose media. To determine the effect of PKC down- gel with ethidium bromide. PCR product bands, visual-
ized by ultraviolet light, were scanned at 300 dots per inchregulation, MCs were treated with 100 nmol/L phorbol
12-myristate 13-acetate (PMA, Sigma Chemical Corpo- and densitometric analysis was done with the National
Institutes of Health Image 1.61 software with availableration, St. Louis, MO, USA) for 24 hours, incubated in
30 mmol/L d-glucose for 3 hours, and harvested for total macro and linear regression analyzer. To confirm the
identity of the VEGF cDNA product, each of the electro-RNA and protein extraction. To avoid any confounding
effects of serum on VEGF production, all experiments phoresed PCR bands was extracted with a DNA extrac-
tion kit (Qiagen, Valencia, CA, USA) and sequencedwere performed in serum-free media.
using an ABI automated DNA sequencing system (ABI
Semiquantitative RT-PCR of VEGF transcripts Genetic Analyzer 310; PRISM, Branchburg Park, NJ,
USA). Quantitation of the VEGF mRNA expressionTotal RNA was extracted from MCs using TRIzol LS
reagent (Life Technologies, Gaithersburg, MD, USA) was corrected by b2m.
and the cDNA was synthesized by a reverse transcription
Measurement of VEGF protein using Western blotreaction of 1 mg of total RNA with oligo-(dT) primers
(Life Technologies, Gaithersburg, MD, USA). Next, 5 mL After incubation in the different culture media, MCs
were lyzed in lysis buffer and centrifuged for 15 minutescDNA was amplified by Taq DNA polymerase in a 25-mL
reaction volume containing 10 mmol/L Tris-HCl (pH at 12,000 rpm. Next, 50 mg protein was electrophoresed
on 12% SDS-polyacrylamide gel and transferred to a nitro-8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 0.2 mmol/L
deoxyribonucleoside triphosphate, and 10 pmol of each cellulose membrane. The blot was incubated at room
temperature on a shaker mechanism in 0.1 ng/mL of anprimer. The polymerase chain reaction (PCR) profile
consisted of initial denaturation at 948C for 7 minutes, anti-VEGF monoclonal antibody (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA, USA). Detection of specificfollowed by 35 cycles (VEGF) or 30 cycles (b2-microglob-
ulin [b2m]) of denaturation at 948C for 30 seconds, an- signals was performed using the ECL Western blotting
detection reagents according to the manufacturer’s recom-nealing at 588C for 30 seconds, extension at 728C for 90
seconds, and extension at 728C for 7 minutes. mendations (Amersham, Buckinghamshire, England).
Two sets of rat VEGF primers, which amplify at least
Measurement of VEGF concentrations in plasma andthree splicing variants of rat VEGF mRNA (VEGF120,
urine of patients with diabetesVEGF164, and VEGF188), were used. The first set (rVEGF1
primer), which includes introns between amplification Seventy-three patients with NIDDM whose serum cre-
atinine was less than 2.0 mg/dL were included for mea-sites from exon 3 to the 39 untranslated end, amplifies
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surement of VEGF levels in plasma and urine according correlation between urinary VEGF and various clinical
to the status of diabetic nephropathy. The amount of parameters, simple regression analysis was used. P ,
VEGF protein was measured by a competitive enzyme 0.05 was considered statistically significant.
immunoassay (EIA) kit (ACCUCYTE Human VEGF;
Cytimmune Science Inc., MD, USA). At that point, 50 mL
RESULTSof a plasma or urine sample with an equal volume of
Effect of various glucose concentrations on VEGFdiluent was dispensed in a 96-microwell plate, precoated
gene expressionwith 25 mL diluted biotinylated rabbit antihuman VEGF
polyclonal antibody. The plate was incubated at room RT-PCR of mRNA from rat MCs using rVEGF1 prim-
temperature for 3 hours, washed five times, and devel- ers showed three alternative splicing variants: bands of
oped with 200 mL of color reagent per well. The intensity 330, 462, and 514 bp corresponding to VEGF120, VEGF164,
of the color was measured in an enzyme-linked immuno- and VEGF188, respectively (Fig. 1). Likewise, RT-PCR
sorbent assay (ELISA) reader. The sensitivity of the amplification using rVEGF2 primers revealed two alter-
ELISA for VEGF was 19.5 pg/mL. native splicing variants: 377 and 439 bp fragments corre-
sponding to VEGF164 and VEGF188, respectively (Fig. 1).Immunohistochemistry
We then addressed the effect of increasing glucose
This study was performed to analyze in detail the ex- concentrations in the culture media on the level of the
pression of VEGF protein in the diabetic kidney. Twenty VEGF transcript. In the normal glucose group, low levels
renal biopsies from patients with NIDDM and three of VEGF isoforms were expressed, and the ratio of
biopsies from patients with renal cell carcinoma under- VEGF164 to b2m was 0.03 6 0.03. However, mRNA
going nephrectomy were studied. In the group with dia- expression of VEGF was incrementally increased in a
betes, the average age of the patients was 50.9 6 14 years glucose concentration–dependent manner. In the me-
(mean 6 standard deviation [SD]); the average daily dium glucose (15 mmol/L d-glucose) group, the ratio of
excretion of urine protein was 2.55 6 1.88 g (mean 6 SD); VEGF164 to b2m was increased to 0.12 6 0.07 at 3 hours,and the average serum creatinine concentration was 1.56 6 0.05 6 0.02 at 6 hours, and 0.03 6 0.01 at 24 hours. The
1.12 mg/dL (mean 6 SD). Renal tissue was obtained VEGF164 to b2m ratio in the high glucose (30 mmol/Lfrom percutaneous biopsy in patients with NIDDM and d-glucose) group was markedly increased to 0.48 6 0.10
from tumor-free parts of the nephrectomy specimen in at 3 hours (P 5 0.016), 0.25 6 0.08 at 6 hours (P 5
patients with renal cell carcinoma. Renal tissue was im-
0.044), and 0.04 6 0.05 at 24 hours (Fig. 2, Table 1).
mediately fixed in 10% neutral buffered formalin, cast
The VEGF120 to b2m ratio was similar to that ofin paraffin, sliced in 3 mm thick sections, and placed on
VEGF164. In the medium glucose group, it was increaseda microscope slide. After removal of paraffin and dehy-
to 0.17 6 0.15 at 3 hours (mL 5 0.03) and 0.09 6 0.03dration in xylene and graded alcohols, the slide was im-
at 6 hours (mL 5 0.043). In the high glucose group, itmersed in distilled water. The kidney section was trans-
was increased to 0.57 6 0.10 at 3 hours (mL 5 0.012)ferred to a 10-mmol/L citrate buffer solution for antigen
and 0.48 6 0.08 at 6 hours (mL 5 0.014) (Fig. 2, Tableretrieval at a pH of 6.0 and then microwaved for 10 min.
2). MCs exposed to 25 mmol/L d-mannitol for 3 hoursAfter another water wash, 0.05% H2O2-methanol was
showed no difference in the expression of VEGF mRNAapplied for 15 minutes to block the endogenous perox-
compared with that found in the normal glucose group.idase. The primary antibody, polyclonal anti-VEGF
(Biogenex, San Ramon, CA, USA), was added at a 1:20 Effect of PKC inhibition on VEGF gene expression
dilution for 2 hours at room temperature. Negative con-
To test whether VEGF expression is mediated by thetrol sections were stained under identical conditions with
PKC system, PMA and calphostin C were used. Treat-the buffer solution substituting for the primary antibody.
ment with calphostin C (200 nmol/L) for 1 hour beforeWith an LSAB kit/HRP (DAKO, Carpinteria, CA, USA),
incubation in high-glucose media markedly decreasedkidney sections were sequentially treated with normal
VEGF164 expression to 0.09 6 0.06 at 3 hours (P 5 0.04)goat serum, primary antibody, link antibody, strep-
and 0.03 6 0.03 at 6 hours (P 5 0.071) compared withtavidin-biotin horseradish peroxidase, and aminoethyl
no calphostin C. Similarly, VEGF120 expression was alsocarbamisole (chromogen). Sections were then counter-
decreased to 0.13 6 0.07 at 3 hours (P 5 0.003) andstained with Mayer’s hematoxylin.
0.05 6 0.03 at 6 hours (P 5 0.014). Treatment of MCs
Statistics with PMA (100 nmol/L) for 24 hours in high-glucose
media prevented the high glucose–induced increases inResults were expressed as mean 6 SD. Comparisons
VEGF164 expression (0.08 6 0.05; P 5 0.034) andwere made by analysis of variance (ANOVA) within
VEGF120 expression (0.06 6 0.05; P 5 0.035) (Fig. 3,groups and by Student’s t-test between groups using a
SPSS for Windows computer application. To analyze the Tables 1 and 2).
Cha et al: VEGF in diabetic nephropathy S-107
Fig. 1. RT-PCR of VEGF in cultured rat
mesangial cells. The three alternative splic-
ing variants encoding peptides VEGF120,
VEGF164, and VEGF188 were identified us-
ing rVEGF1 primers. Two splicing variants,
VEGF164 and VEGF188, were identified using
rVEGF2 primers. VEGF120 and VEGF164 were
expressed more highly than VEGF188, which
was faintly expressed.
Fig. 2. The effect of glucose concentration on
mRNA expression of VEGF. VEGF expres-
sion was increased in high glucose media and
reached a peak value in 30 mmol/L d-glucose
at 3 hours’ incubation. The expression of
VEGF120 and VEGF164 was higher than that of
VEGF188. NG, normal glucose; MG, medium
glucose; HG, high glucose
Table 2. VEGF120 mRNA expression in each experimental conditionTable 1. VEGF164 mRNA expression in each experimental condition
Hours of incubation Hours of incubation
Glucose orGlucose or
treatment group 0 3 6 24 treatment group 0 3 6 24
NG 0.0460.03 — — —NG 0.0360.03 — — —
MG — 0.1260.07 0.0560.02 0.0360.01 MG — 0.1760.15* 0.1960.03* 0.0360.02
HG — 0.5760.10* 0.4860.08* 0.0460.04HG — 0.4860.10* 0.2560.08* 0.0460.05
Cal — 0.0960.06† 0.0360.03 — Cal — 0.1360.07† 0.0560.03† —
PMA — 0.0660.05† — —PMA — 0.0860.05† — —
Results are shown as VEGF120/b2m mRNA densitometric recording ratio. DataResults are shown as VEGF164/b2m mRNA densitometric recording ratio. Data
are expressed as mean 6 SD. NG, normal glucose group; MG, medium glucose are expressed as mean 6 SD. NG, normal glucose group; MG, medium glucose
group; HG, high glucose group; Cal, calphostin C-treated group; PMA, phorbolgroup; HG, high glucose group; Cal, calphostin C-treated group; PMA, phorbol
myristate acetate-treated group. myristate acetate-treated group.
* P , 0.05 compared with normal glucose group at 0 hour incubation.* P , 0.05 compared with normal glucose group at 0 hour incubation.
† P , 0.05 compared with high glucose group at 3 hours of incubation. † P , 0.05 compared with high glucose group at 3 hours of incubation.
in the normal glucose group but increased in a glucose
Western blot analysis of VEGF production in concentration–dependent manner, peaking at 3 hours.
cultured MCs Likewise, pretreatment with PMA or calphostin C mark-
VEGF protein in MCs was detected as a single band edly decreased production of VEGF protein in the high-
of approximately 42 kDa. Similar to the findings with glucose group. Moreover, d-mannitol had no effect on
VEGF protein production at 3 h (Fig. 4).VEGF mRNA, VEGF protein expression remained low
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Immunohistochemical staining for VEGF in the
diabetic kidney
In the normal kidney, VEGF protein was clearly de-
tected in the glomerular visceral epithelial cells, evi-
denced by strong cytoplasmic staining, but not in mesan-
gial and endothelial cells (Fig. 5A). In the renal tubule
compartment, all positively stained cells showed a cyto-
plasmic pattern (Fig. 5B), which was focally increased in
the distal tubular epithelial cells and faint in the proximal
tubular cells. VEGF staining was markedly different in
the diabetic vs. the normal kidney with changes primarily
localized in the glomerular mesangium. Biopsy results
showing mild changes of diabetic nephropathy stained
more heavily for VEGF in the glomerular visceral epithe-
lial and distal tubular cells than those of control kidneys
(Fig. 5C). In contrast, the biopsy results showing ad-
vanced changes of diabetic nephropathy, such as severeFig. 3. The effect of PKC inhibitor (calphostin C) and PKC down-
mesangial sclerosis and mesangial expansion, showedregulator (PMA) on VEGF mRNA expression. VEGF mRNA expres-
sion was significantly decreased with calphostin C and PMA treatment. markedly decreased and sometimes negative VEGF
Mannitol had no effect on VEGF expression. 1: negative control, 2: staining in globally sclerotic glomeruli (Fig. 5D). Inter-
normal glucose at 0 hour, 3: high glucose at 3 hours, 4: calphostin C in
estingly however, VEGF staining in the tubule compart-high glucose at 3 hours, 5: calphostin C in high glucose at 6 hours, 6:
calphostin C in high glucose at 24 hours, 7: PMA in high glucose at 3 ment, particularly the proximal segment, remained more
hours, and 8: mannitol at 3 hours. intense in the biopsies of patients with late diabetic ne-
phropathy than in those of early nephropathy (Fig. 5E).
VEGF concentration in plasma and urine in patients DISCUSSION
with diabetes We demonstrate that the rat mesangial cell cultured
in high-glucose media transiently up-regulates its expres-In the study, 73 patients with NIDDM whose serum
sion of VEGF mRNA and protein, which arise as threecreatinine level was less than 2.0 mg/dL were included.
alternative splicing variants. This finding agrees with aPatients were classified according to the status of their
previous report that showed that human mesangial cellsdiabetic nephropathy (37 cases with normoalbuminuria,
are capable of producing VEGF [9]. Williams et al [10]23 with microalbuminuria, and 13 with overt protein-
reported that vascular smooth muscle cells grown in high-uria). Baseline clinical and biochemical characteristics
glucose media overexpress VEGF through the PKC path-of the study population are shown in Table 3. Plasma
way. Considering that MCs share properties with smoothVEGF concentration was significantly higher in the pa-
muscle cells, this raises the possibility that MCs can pro-tients with overt proteinuria (1219.2 6 463.9 pg/mL) than
duce VEGF through a PKC-dependent mechanism.in patients with normoalbuminuria (937.0 6 429.7 pg/mL)
The MC is apposed to the glomerular capillary endo-and microalbuminuria (857.8 6 455.6 pg/mL) (P , 0.05).
thelial cell, which possesses receptors for VEGF [11, 12].Plasma VEGF level did not differ between patients with
This anatomic relationship may allow the locally pro-normoalbuminuria and those with microalbuminuria.
duced VEGF by MCs to directly influence glomerularUrinary excretion of VEGF was significantly increased
endothelial cell function. Diabetes results in several pa-
according to the degree of microalbuminuria and pro- thobiologic changes, such as activation of PKC, up-regu-
teinuria. Urinary VEGF concentration was 57.2 6 87.9 lation of cytokines and growth factors including trans-
pg/mg Cr in normoalbuminuric patients, 122.7 6 75.1 in forming growth factor (TGF)-b, and stimulation of the
microalbuminuric patients, and 288.4 6 119.3 in overtly renin-angiotensin system [13–19], which are all known
proteinuric patients (P , 0.05). The level of urinary to increase renal VEGF production. Therefore, the mes-
VEGF was also weakly but significantly correlated with angial cell in the diabetic state may be plausibly expected
the levels of serum creatinine (r 5 0.389; P 5 0.001), to augment its production of VEGF. In the present study,
microalbuminuria (r 5 0.308; P , 0.05), proteinuria (r 5 VEGF expression peaked at 3 hours in the high-glucose
0.491; P , 0.0001), and creatinine clearance (r 5 20.327; group, and VEGF production was increased in a glucose
P , 0.05). In a multiple regression analysis, the 24-hour concentration–dependent manner. This finding is similar
urine protein excretion and serum creatinine concentra- to that of a study in which VEGF production peaked at
tion were independently associated with the urinary 3 hours in vascular smooth muscle cells cultured in high-
glucose solution [10].VEGF level.
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Fig. 4. Western blot analysis of VEGF pro-
duction. Distinct bands of VEGF dimers were
detected at approximately 42 kDa. The VEGF
peptide was increased in high glucose media,
particularly at 3 hours’ incubation. VEGF
production was markedly suppressed in the
calphostin C- or PMA-treated group. NG,
normal glucose; MG, medium glucose; HG,
high glucose; Cal, calphostin C-treated group;
P, PMA-treated group; M, mannitol-treated
group.
Table 3. Baseline clinical and biochemical characteristics of the unclear whether they perform different biologic func-
study population
tions in vivo [12]. Alternative splicing of VEGF mRNA
Normo- Micro- Overt occurs in a tissue-specific manner, and the relative abun-
Parameter albuminuria albuminuria proteinuria dance of each variant differs among the tissue types
Age years 51.3617.8 53.6613.8 57.368.8 [12, 25]. In the kidney, VEGF164 is the most abundantSystolic BP mm Hg 122.4614.3 131.9616.6 143.3621.9‡
product of the VEGF gene, but in this study, glucose-Diastolic BP mmHg 79.767.5 81.167.6 83.367.8
HbA1C % 8.662.2 8.962.0 8.561.7 induced expression of VEGF120 was slightly higher than
BUN mg/dL 15.265.8 23.9631.9 26.7619.7 that of VEGF164 in rat MCs.Creatinine mg/dL 0.7860.25 0.7860.20 1.6260.33‡
VEGF is strongly implicated in the pathogenesis ofCholesterol mg/dL 181640 180646 190651
Albumin g/dL 4.1860.46 4.0460.59 3.3660.60‡ diabetic microvascular complications because it increases
CCr mL/min 131647 133651 55629‡ vascular permeability to macromolecules and stimulates24 h proteinuria mg/day 2936206 5416399 440063411‡
monocyte chemotaxis and tissue factor production, allMicroalbuminuria mg/day 12.666.9 107.3681.1* 10436998‡
Plasma VEGF pg/mL 9496439 8616478 12156484 of which can contribute to microvascular complications
Urine VEGF pg/mg Cr 60.2689.5 128.7675.4† 286.06124.3‡ [26, 27]. Although the role of VEGF in regulating glo-
Results are given as mean 6 standard deviation. Comparisons are made merular permeability has not yet been defined, it canbetween the normoalbuminuric group, microalbuminuric group, and the overt
proteinuric group. Number of patients is 37 in the normoalbuminuric group, 23 potentially mediate glomerular proteinuria in diabetic
in the microalbuminuric group, and 13 in the overt proteinuric group. Statistically nephropathy. The mechanism of increased vascular per-significant difference vs. normoalbuminuric patients: * P , 0.05, † P , 0.001,
‡ P , 0.0001 meability by VEGF may involve stimulation of collagen-
ase production and proteolytic disruption of the endo-
thelial basement membrane [28]. Antonetti et al [29, 30]
reported that vascular permeability in experimental dia-That high ambient glucose causes an early, but not
betes is associated with reduced endothelial occludin, asustained, release of VEGF in vitro seems to argue
tight junction protein between endothelial cells.against a role for VEGF in diabetic nephropathy, but
With regard to vascular permeability, Williams et alprolonged hyperglycemia and other consequences of the
[abstract; Diabetes 45(Suppl 2):66A, 1996] showed thatdiabetic state in vivo may alter the relative balance
an acute infusion of VEGF into experimental animalsamong various growth factors and cytokines such that
markedly increased sciatic nerve and aortic albumin per-VEGF production may be sustained for a longer period
meability. It is tempting to speculate that the VEGF[20–23]. In the present study, high glucose–induced
produced by MCs may act as a paracrine factor to influ-VEGF synthesis was abolished by PKC inhibition or
ence glomerular protein permselectivity.down-regulation, which suggests that PKC pathways are
In this study, urinary excretion of VEGF in peopleinvolved in VEGF production in MCs. It is thus possible
with type 2 diabetes was significantly increased with pro-that a PKC inhibitor may help to prevent overproduction
gression from microalbuminuria to overt proteinuria andof VEGF in diabetes.
was correlated with the levels of serum creatinine and theConsistent with a previous study [9], RT-PCR results
degree of proteinuria. Whether the increase in urinaryrevealed that rat MCs express mRNA splicing variants
VEGF excretion is a primary cause or a secondary effectcorresponding to the VEGF120, VEGF164, and VEGF188
of diabetic nephropathy remains unanswered.isoforms. All three transcripts, especially those of VEGF120
It has been reported that the kidney, particularly theand VEGF164, appear to be up-regulated by high-glucose
glomerulus, is a major source of VEGF production inmedia. VEGF120 and VEGF164 are secreted isoforms that
humans [31, 32]. This study showed that the VEGF pro-bind with high affinity to the vascular endothelium
tein is localized primarily in the glomerular epithelialthrough two specific tyrosine kinase receptors [24]. Al-
cells and to a lesser extent in the distal tubular epithelialthough differences in the biologic activities of these dif-
ferent splicing variants have been reported, it remains cells in the normal kidney, consistent with the findings of
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Fig. 5. Immunohistochemistry of VEGF in control and diabetic kid-
neys. (A) Normal control glomeruli with positive staining for VEGF
with labeling of visceral epithelial cells (short arrow). (B) Focally posi-
tive staining for VEGF in distal tubules in control kidney (P, proximal
tubule; D, distal tubule, arrow). (C) Early diabetic glomeruli revealed
stronger VEGF staining than control glomeruli in visceral epithelial
cells (short arrow). (D) Advanced sclerotic glomeruli showed markedly
decreased staining for VEGF. (E) Tubular staining for VEGF in the
more advanced diabetic kidney. VEGF staining decreased in the glo-
merulus but markedly increased in the proximal tubular segment (ar-
rowhead). Magnification: A, C, and D, 3400; B and E, 3200.
previous reports [33, 34]. One can speculate that VEGF, contribute to the early changes of diabetic nephropathy.
However, the small number of patients in this study withconstitutively produced by the podocyte, may play some
role in regulating the glomerular permeability to protein. an early diabetic lesion precludes any definitive conclu-
sions about the role of VEGF in this stage of the disease.VEGF staining in the diabetic kidney demonstrated
marked differences with respect to degree of the glomer- Pathologic findings differed somewhat from those of
urinary VEGF levels. Even though VEGF staining inular mesangial expansion. Interestingly, biopsies of pa-
tients who had experienced mild changes of diabetic the glomerulus decreased with worsening of diabetic ne-
phropathy, VEGF excretion in the urine increased withnephropathy showed greater VEGF staining in the glo-
merulus than biopsies of control specimens. Although this progression of proteinuria. Patients with early diabetic
nephropathy, evidenced by microalbuminuria, may pro-does not establish causality, up-regulation of VEGF may
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lar permeability factor: isolation from U937 cells. J Biol Chem 264:duce most of their VEGF from glomerular visceral epi-
20017–20024, 1989
thelial cells. In contrast, patients with more advanced 4. Gilbert RE, Vranes D, Berka JL, Kelly DJ, Cox A, Wu LL,
Stacker SA, Cooper ME: Vascular endothelial growth factor andnephropathy, evidenced by global sclerosis and overt
its receptors in control and diabetic rat eyes. Lab Invest 78:1017–proteinuria, may produce much of their VEGF in the
1027, 1998
tubules, especially proximally, which demonstrated a 5. Mathews MK, Merges C, Mcleod S, Lutty GA: Vascular endo-
thelial growth factor and vascular permeability changes in humanmarked up-regulation of VEGF staining. It is possible
diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2729–2741, 1997that as nephropathy progresses, increased tubular epi-
6. Stehouwer CDA, Schaper NC: The pathogenesis of vascular com-
thelial VEGF production more than compensates for plications of diabetes mellitus: One voice or many? Eur J Clin
Invest 26:535–543, 1996decreased glomerular VEGF production.
7. Stehouwer CDA, Donker AJM: Urinary albumin excretion andThe renal tubule is subject to both direct and indirect
cardiovascular disease risk in diabetes mellitus: Is endothelial dys-
pathogenetic influences because of its position in the function the missing link? J Nephrol 6:72–92, 1993
8. Cha DR, Feld SM, Nast C, Lapage J, Adler SG: Apoptosis innephron and its reabsorptive function [35–37]. In the
mesangial cells induced by ionizing radiation and cytotoxic drugs.diabetic state, the tubule, particularly the proximal seg-
Kidney Int 50:1565–1571, 1996
ment, is directly exposed to glomerular effluents includ- 9. Lijima K, Yoshikawa N, Connolly DT, Nakamura H: Human
mesangial cells and peripheral blood mononuclear cells produceing glucose, large amounts of protein, advanced glycosyl-
vascular permeability factor. Kidney Int 44:959–966, 1993ation end products, and other substances. Many of these
10. Williams B, Gallacher B, Pate H, Orme C: Glucose induced
activate various cytokines and growth factors including protein kinase C activation regulates vascular permeability factor
mRNA expression and peptide production by human vascularTGF-b and VEGF.
smooth muscle cells in vitro. Diabetes 46:1497–1503, 1997Conversely, tubular ischemia can result from increased
11. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular
metabolic demand on the tubules or reduced peritubular endothelial growth factor (VEGF) and its receptors. FASEB J
13:9–22, 1999blood flow [38]. In this regard, the S3 segment of the
12. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Up-proximal tubule may be particularly vulnerable to ische-
regulation of vascular endothelial growth factor/vascular perme-
mia, which is a potent inducer of VEGF production [39]. ability factor receptor system in experimental background retinop-
athy of the rat. Diabetes 47:401–406, 1998Additional studies will be needed to formally address
13. Mauer SM, Steffes MW, Brown DM: The kidney in diabetes.these issues. Am J Med 70:603–612, 1981
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statin inhibits proliferation of rat mesangial cells. J Clin Investdia transiently increases VEGF mRNA expression and
91:83–87, 1993protein production in rat MCs through a PKC-dependent 15. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino
mechanism. Urinary excretion of VEGF significantly in- Y, Koide H: mRNA expression of growth factors in glomeruli
from diabetic rats. Diabetes 42:450–456, 1993creases according to the stage of diabetic nephropathy,
16. Shankland SJ, Scholey JW, Ly H, Thai K: Expression of trans-and it also weakly but significantly correlates with the forming growth factor-b1 during diabetic renal hypertrophy. Kid-
level of serum creatinine, creatinine clearance, and degree ney Int 46:430–442, 1994
17. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with up-of proteinuria. Pronounced up-regulation of VEGF is
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nephropathy, whereas a marked increase in VEGF is found 18. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege
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